This is the first study to measure prolactin levels in transgender patients receiving the standard feminizing hormone therapy regimen that’s used in the US. The study demonstrates that gender-affirming treatment for transgender individuals may be safer than initially thought.
Transgender Health AMA Series: I’m Joshua Safer, Medical Director at the Center for Transgender Medicine and Surgery at Boston University Medical Center, here to talk about the science behind transgender medicine, AMA! : science:
“I’m Joshua Safer and I serve as the Medical Director of the Center for Transgender Medicine and Surgery at Boston Medical Center and Associate Professor of Medicine at the BU School of Medicine. I am a member of the Endocrine Society task force that is revising guidelines for the medical care of transgender patients, the Global Education Initiative committee for the World Professional Association for Transgender Health (WPATH), the Standards of Care revision committee for WPATH, and I am a scientific co-chair for WPATH’s international meeting. My research focus has been to demonstrate health and quality of life benefits accruing from increased access to care for transgender patients and I have been developing novel transgender medicine curricular content at the BU School of Medicine.”